Printer Friendly

Avillion Opens IND for Phase 2 Study of Anti-IL-17 A/F Nanobody for treatment of Psoriasis.

M2 PHARMA-February 20, 2018-Avillion Opens IND for Phase 2 Study of Anti-IL-17 A/F Nanobody for treatment of Psoriasis


- London, UK-based drug development company Avillion LLP has opened an investigational new drug application for a Phase 2 study in plaque psoriasis under its co-development agreement with science and technology company Darmstadt, Germany-based Merck, the company said.

Avillion and Merck signed a co-development agreement in 2017 under which Avillion will develop and finance the development of M1095, Merck's anti IL-17 A/F nanobody from Phase 2 through Phase 3 to regulatory submission.

The new trial with M1095 is a Phase 2b randomised, double-blind, placebo controlled, multi-centre study designed to assess its efficacy, safety and tolerability in up to 300 subjects with moderate to severe chronic plaque-type psoriasis.

The Anti IL-17 A/F nanobody M1095 is an investigational bi-specific half-life-extended nanobody that is thought to neutralise both IL-17A and IL-17F with the potential to treat inflammatory diseases. Due to the small size and unique structure of nanobodies, they could be an ideal building block for a new generation of novel biological drugs.

Merck acquired full, exclusive rights to anti IL-17 A/F nanobody through a global development and commercialisation deal with Ablynx in 2013. Avillion entered into a co-development agreement with Merck for the Phase 2 and Phase 3 development of the candidate in March 2017.

Avillion LLP is focused on the co-development and financing of pharmaceutical candidates from proof-of-concept through to regulatory approval.

The company offers the opportunity to partner assets from post proof-of-concept through to regulatory approval globally and to accelerate their development and hence availability to patients.

Its objective is to enable its partners to continue to develop the drug candidates in their pipeline whilst maintaining quality data without increasing the burden on their P and L or cash reserves.

((Comments on this story may be sent to

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Feb 20, 2018
Previous Article:Eurofins BPT Munich to Market SenzaGen GARD tests.
Next Article:AbbVie Phase 2b Data Show Upadacitinib Reduces Pruritis in Atopic Dermatitis as Early as Week One.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters